Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.58 |
| ▸ | ITGAV | P06756 | 13/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7212645 | 0.90 | ITGB3 (0.60) | ITGB3ITGAVLMNAITGA2BITGB5 | |
| SCHEMBL7211708 | 0.83 | ITGB3 (0.76) | ITGB3ITGAVLMNAITGA2B | |
| SCHEMBL7397240 | 0.71 | ITGB3 (0.76) | ITGB3ITGAVLMNAITGA2BPOLB | |
| SCHEMBL7217699 | 0.69 | ITGB3 (0.51) | ITGB3ITGAVLMNAITGA2BPOLB | |
| SCHEMBL606801 | 0.65 | ITGAV (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5066046 | 0.65 | ITGAV (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7211510 | 0.65 | ITGB3 (0.52) | ITGB3ITGAVLMNAITGA2BPOLB | |
| SCHEMBL7216485 | 0.63 | ITGB3 (0.86) | ITGB3ITGAVITGA2B | |
| SCHEMBL5028393 | 0.61 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL5879592 | 0.58 | ITGB3 (0.43) | ITGB3ITGAVPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20130012683-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-8303973-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG | 2012-10-04 | — | — | US | disclosed |
| US-20050152945-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-14 | — | — | US | disclosed |
| US-20050149157-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050149080-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050149158-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050143817-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| WO-2005051232-A2 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050152946-A1 | Implantable sensors and implantable pumps and anti-scarring agents | MMP1, CDKN1A, MKI67 | ITGB3 827/4885ITGAV 727/4885LMNA 3440/4885 |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | MMP1, COL2A1, FN1 | ITGB3 625/4885ITGAV 1232/4885LMNA 1905/4885 |
| US-20120252905-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | ITGB3 29/4885ITGAV 38/4885LMNA 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.